Burning Rock Biotech Limited
NASDAQ Global MarketTotal Valuation
Burning Rock Biotech Limited carries a market capitalization of 9.08M, placing it among publicly traded companies globally. Its enterprise value stands at 788.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.08M |
| Enterprise Value | 788.45M |
Share Statistics
Burning Rock Biotech Limited currently has 105.46M shares outstanding.
| Shares Outstanding | 105.46M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.30, and the price-to-book ratio stands at -0.28.
| PE Ratio | N/A |
| PS Ratio | 2.30 |
| PB Ratio | -0.28 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | -34.59 |
| P/OCF Ratio | -34.59 |
Enterprise Valuation
| EV / Sales | 1.53 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Burning Rock Biotech Limited maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.85, indicating elevated leverage, while an interest coverage ratio of -1,300.24 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.05 |
| Quick Ratio | 2.71 |
| Debt / Equity | 9.85 |
| Debt / EBITDA | -0.87 |
| Interest Coverage | -1,300.24 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -7.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.19 |
Taxes
| Income Tax | 1.56M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Burning Rock Biotech Limited's stock has gained approximately 153.39233% over the past 52 weeks. The 50-day moving average sits at 15.48, while the 200-day moving average is 17.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | 153.39233% |
| 50-Day Moving Average | 15.48 |
| 200-Day Moving Average | 17.65 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Burning Rock Biotech Limited generated 514.43M in revenue and converted that into -59.32M in net income, yielding earnings per share of -5.58. EBITDA reached -58.51M, while operating income came in at -58.51M.
| Revenue | 514.43M |
| Gross Profit | 383.52M |
| Operating Income | -58.51M |
| Pretax Income | -57.75M |
| Net Income | -59.32M |
| EBITDA | -58.51M |
| EBIT | -58.51M |
| Earnings Per Share (EPS) | -5.58 |
Balance Sheet
Burning Rock Biotech Limited holds 446.00M in cash and equivalents against 50.86M in total debt, resulting in a net debt position of -444.10M. Total book value stands at -4.27B, with working capital of 471.18M providing operational flexibility.
| Cash & Cash Equivalents | 446.00M |
| Total Debt | 50.86M |
| Net Debt | -444.10M |
| Equity (Book Value) | -4.27B |
| Book Value Per Share | -401.79 |
| Working Capital | 471.18M |
Cash Flow
Burning Rock Biotech Limited produced -34.22M in operating cash flow over the past twelve months.
| Operating Cash Flow | -34.22M |
| Capital Expenditures | N/A |
| Free Cash Flow | -34.22M |
| FCF Per Share | -3.22 |
Margins
Burning Rock Biotech Limited operates with a gross margin of 74.55, reflecting its pricing power and cost economics. The operating margin of -11.37 and net profit margin of -11.53 provide insight into operational efficiency.
| Gross Margin | 74.55 |
| Operating Margin | -11.37 |
| Pretax Margin | -11.23 |
| Profit Margin | -11.53 |
| EBITDA Margin | -11.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.16 |
| FCF Yield | -2.89 |
Stock Splits
Burning Rock Biotech Limited's most recent stock split took place on May 15, 2024 with a 10:1 split ratio.
| Last Split Date | 5/15/2024 |
| Split Ratio | 10:1 |
Scores
Burning Rock Biotech Limited posts an Altman Z-Score of -3.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.85 |